Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
7.45B
Market cap7.45B
Price-Earnings ratio
25.22
Price-Earnings ratio25.22
Dividend yield
Dividend yield
Average volume
1.38M
Average volume1.38M
High today
$64.69
High today$64.69
Low today
$62.69
Low today$62.69
Open price
$64.56
Open price$64.56
Volume
1.54M
Volume1.54M
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $63.08. The company's market cap stands at 7.45B, with a P/E ratio of 25.22.

On 2026-04-07, Halozyme Therapeutics(HALO) stock traded between a low of $62.69 and a high of $64.69. Shares are currently priced at $63.08, which is +0.6% above the low and -2.5% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 1.54M, against a daily average of 1.38M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $82.22 and a 52-week low of $47.50.

HALO News

Simply Wall St 23h
How Investors May Respond To Halozyme Therapeutics Mixed Q4 Results And ENHANZE-Focused Guidance Shift

In Q4 2025, Halozyme Therapeutics reported EPS of US$0.24 and revenue of US$451.77 million, exceeding revenue expectations but falling short on earnings, while...

How Investors May Respond To Halozyme Therapeutics Mixed Q4 Results And ENHANZE-Focused Guidance Shift

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.